Finance
Results: 3157-3168 of 41643

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼

Court Authorizes Notice of Proposed Class Action Settlement for Farmers, Landscapers and Others Exposed to Weed Killers








